174 related articles for article (PubMed ID: 33590389)
1. Stimulated saliva secretion is reduced in proton pump inhibitor-resistant severe reflux esophagitis patients.
Tanabe T; Koeda M; Kitasako Y; Momma E; Hoshikawa Y; Hoshino S; Kawami N; Kaise M; Iwakiri K
Esophagus; 2021 Jul; 18(3):676-683. PubMed ID: 33590389
[TBL] [Abstract][Full Text] [Related]
2. Saliva secretion is reduced in proton pump inhibitor-responsive non-erosive reflux disease patients.
Koeda M; Tanabe T; Kitasako Y; Momma E; Hoshikawa Y; Hoshino S; Kawami N; Kaise M; Iwakiri K
Esophagus; 2021 Oct; 18(4):900-907. PubMed ID: 33886014
[TBL] [Abstract][Full Text] [Related]
3. Saliva secretion is reduced in mild reflux esophagitis patients.
Koeda M; Tanabe T; Kitasako Y; Momma E; Hoshikawa Y; Hoshino S; Kawami N; Kaise M; Iwakiri K
Esophagus; 2022 Apr; 19(2):351-359. PubMed ID: 34536162
[TBL] [Abstract][Full Text] [Related]
4. Proton Pump Inhibitor Treatment Has Little Effects on Secretion of Saliva in Patients with Proton Pump Inhibitor-Responsive Mild Reflux Esophagitis and Non-Erosive Reflux Disease.
Hoshikawa Y; Momma E; Hoshino S; Kawami N; Kitasako Y; Ikeda M; Iwakiri K
Digestion; 2023; 104(3):187-192. PubMed ID: 36580899
[TBL] [Abstract][Full Text] [Related]
5. Differences in salivary secretion and epidermal growth factor concentrations in mild reflux esophagitis and non-erosive reflux disease.
Koeda M; Momma E; Tanabe T; Kitasako Y; Hoshikawa Y; Hoshino S; Kawami N; Iwakiri K
Esophagus; 2023 Apr; 20(2):317-324. PubMed ID: 36344779
[TBL] [Abstract][Full Text] [Related]
6. Saliva Secretion Is Significantly Lower in Female Patients with Mild Reflux Esophagitis than in Female Healthy Controls.
Momma E; Koeda M; Hoshikawa Y; Tanabe T; Hoshino S; Kitasako Y; Kawami N; Iwakiri K
Digestion; 2023; 104(4):299-305. PubMed ID: 36750039
[TBL] [Abstract][Full Text] [Related]
7. In females, salivary secretion was significantly lower in patients with severe reflux esophagitis than in healthy controls.
Hoshino S; Momma E; Koeda M; Hoshikawa Y; Tanabe T; Kawami N; Kitasako Y; Iwakiri K
Esophagus; 2024 Jul; 21(3):383-389. PubMed ID: 38536601
[TBL] [Abstract][Full Text] [Related]
8. The Effects of Switching to Vonoprazan, a Novel Potassium-Competitive Acid Blocker, on Gastric Acidity and Reflux Patterns in Patients with Erosive Esophagitis Refractory to Proton Pump Inhibitors.
Yamashita H; Kanamori A; Kano C; Hashimura H; Matsumoto K; Tsujimae M; Yoshizaki T; Momose K; Obata D; Eguchi T; Fujita M; Okada A
Digestion; 2017; 96(1):52-59. PubMed ID: 28662503
[TBL] [Abstract][Full Text] [Related]
9. Risk of hemorrhage and stricture significantly increases in elderly patients with proton pump inhibitor (PPI)-resistant reflux esophagitis.
Takenouchi N; Hoshino S; Hoshikawa Y; Tanabe T; Koeda M; Momma E; Ishikawa Y; Kawami N; Kaise M; Iwakiri K
Esophagus; 2020 Jan; 17(1):87-91. PubMed ID: 31679094
[TBL] [Abstract][Full Text] [Related]
10. Pathogenesis of Double-Dose Proton Pump Inhibitor-Resistant Non-Erosive Reflux Disease, and Mechanism of Reflux Symptoms and Gastric Acid Secretion-Suppressive Effect in the Presence or Absence of Helicobacter pylori Infection.
Kawami N; Takenouchi N; Umezawa M; Hoshino S; Hanada Y; Hoshikawa Y; Sano H; Hoshihara Y; Nomura T; Uchida E; Iwakiri K
Digestion; 2017; 95(2):140-145. PubMed ID: 28161707
[TBL] [Abstract][Full Text] [Related]
11. Similarities and differences among eosinophilic esophagitis, proton-pump inhibitor-responsive esophageal eosinophilia, and reflux esophagitis: comparisons of clinical, endoscopic, and histopathological findings in Japanese patients.
Jiao D; Ishimura N; Maruyama R; Ishikawa N; Nagase M; Oshima N; Aimi M; Okimoto E; Mikami H; Izumi D; Okada M; Ishihara S; Kinoshita Y
J Gastroenterol; 2017 Feb; 52(2):203-210. PubMed ID: 27108416
[TBL] [Abstract][Full Text] [Related]
12. Treatment Strategy for Standard-Dose Proton Pump Inhibitor-Resistant Reflux Esophagitis.
Iwakiri K
J Nippon Med Sch; 2017; 84(5):209-214. PubMed ID: 29142181
[TBL] [Abstract][Full Text] [Related]
13. Characteristics of proton pump inhibitor-resistant severe reflux esophagitis and efficacy of vonoprazan in elderly (older than 75 years) and non-elderly groups.
Hoshino S; Momma E; Motomiya R; Tanabe T; Koeda M; Hoshikawa Y; Kawami N; Iwakiri K
JGH Open; 2024 Jan; 8(1):e13023. PubMed ID: 38268954
[TBL] [Abstract][Full Text] [Related]
14. Risk factors for resistance to proton pump inhibitor maintenance therapy for reflux esophagitis in Japanese women over 60 years.
Watanabe A; Iwakiri R; Yamaguchi D; Higuchi T; Tsuruoka N; Miyahara K; Akutagawa K; Sakata Y; Fujise T; Oda Y; Shimoda R; Sakata H; Fujimoto K
Digestion; 2012; 86(4):323-8. PubMed ID: 23128344
[TBL] [Abstract][Full Text] [Related]
15. Significantly Lower Saliva Secretion in Females With Gastroesophageal Reflux Disease and Healthy Subjects Than in Males.
Momma E; Koeda M; Hoshikawa Y; Tanabe T; Hoshino S; Kawami N; Iwakiri K
Cureus; 2023 May; 15(5):e39020. PubMed ID: 37323355
[TBL] [Abstract][Full Text] [Related]
16. Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole.
Holtmann G; Cain C; Malfertheiner P
Gastroenterology; 1999 Jul; 117(1):11-6. PubMed ID: 10381904
[TBL] [Abstract][Full Text] [Related]
17. Secretion of epidermal growth factor in saliva of duodenal ulcer patients; an association with Helicobacter pylori eradication and erosive esophagitis.
Kiluk A; Namiot DB; Namiot Z; Leszczyńska K; Kurylonek AJ; Kemona A
Adv Med Sci; 2008; 53(2):305-9. PubMed ID: 18930874
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of long-term maintenance therapy with 10-mg vonoprazan for proton pump inhibitor-resistant reflux esophagitis.
Tanabe T; Hoshino S; Kawami N; Hoshikawa Y; Hanada Y; Takenouchi N; Goto O; Kaise M; Iwakiri K
Esophagus; 2019 Oct; 16(4):377-381. PubMed ID: 31119492
[TBL] [Abstract][Full Text] [Related]
19. Multimodality evaluation of patients with gastroesophageal reflux disease symptoms who have failed empiric proton pump inhibitor therapy.
Galindo G; Vassalle J; Marcus SN; Triadafilopoulos G
Dis Esophagus; 2013 Jul; 26(5):443-50. PubMed ID: 22862422
[TBL] [Abstract][Full Text] [Related]
20. Concomitant irritable bowel syndrome is associated with failure of step-down on-demand proton pump inhibitor treatment in patients with gastro-esophageal reflux disease.
Wu JC; Lai LH; Chow DK; Wong GL; Sung JJ; Chan FK
Neurogastroenterol Motil; 2011 Feb; 23(2):155-60, e31. PubMed ID: 21087355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
